CONTERA PHARMA A/S: Financial statements 2022
CVR: 33062214
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -44,831,824 and a net result of DKK -56,868,331 compared with DKK -31,518,831 the year before. Equity in the 2022 report amounted to DKK 106,573,750. The solvency ratio was 92.1%. The company had 14 employees in the financial year.
- Gross Profit
- DKK -44,831,824
- Profit/Loss
- DKK -56,868,331
- Equity
- DKK 106,573,750
- Total Assets
- DKK 115,742,831
- Employees
- 14
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -44.8 mio. | -56.9 mio. | 106.6 mio. | 14 |
| 2021 | - | -24.2 mio. | -31.5 mio. | 163.4 mio. | 13 |
| 2020 | - | -9.7 mio. | -12.3 mio. | 195 mio. | 4 |
| 2019 | - | -1.2 mio. | -2 mio. | 17.8 mio. | 1 |
| 2018 | - | 1.5 mio. | -968 t. | 3.2 mio. | 2 |
Official annual report
Keep an eye on CONTERA PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of July 1, 2022, Thomas Nikolaj Sager has joined the board of directors of CONTERA PHARMA A/S.
As of July 1, 2022, WooHyun Lee has joined the board of directors of CONTERA PHARMA A/S.
CONTERA PHARMA A/S has published its annual report for 2021. Gross profit came to DKK -24,154,462, and the net result was DKK -31,518,831.
As of March 28, 2022, Sung Joon Kim has joined the board of directors of CONTERA PHARMA A/S.
As of March 28, 2022, Eun Ju Kim has left the board of directors of CONTERA PHARMA A/S.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.